2021 saw expanded use of telehealth and decentralized trials, further proliferation of health misinformation and the launch of various efforts to tackle health disparities. Following in the footsteps of tumultuous 2020, it was a year of widespread changes in the healthcare industry — even for longstanding issues like drug pricing reform, which might actually be tackled in earnest this time around.
So what’s next? Some execs anticipate the increased importance of real-world data in the drug approval process, others are placing their bets on improved orchestration in omnichannel marketing. Here’s what 18 experts shared with MM+M.
(responses have been edited for clarity and brevity)